UBS raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $39 from $36 and keeps a Buy rating on the shares. Checks with key opinion leaders increase the firm’s confidence in the likelihood of a ACP-101 study win, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- Acadia Pharmaceuticals names Katcheves Chief Business and Strategy Officer
- Acadia Pharmaceuticals price target raised to $36 from $32 at UBS
- ACADIA Pharmaceuticals: Strong Growth and Undervalued Pipeline Support Buy Rating
- ACADIA Pharmaceuticals Reports Strong Q2 2025 Earnings
- Acadia Pharmaceuticals price target raised to $24 from $23 at Mizuho